|
Leukemia, Myelocytic, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High BAALC expression predicted for a shorter DFS (P = 0.0152) and OS (P = 0.0210) compared with AML with low BAALC expression; 53.7% of normal-karyotype AML had neither FLT3-ITD nor CEBPA mutations.
|
15746041 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Four prognostic biomarkers-the internal tandem duplication and point mutations in the FLT3 gene, partial tandem duplication of the MLL gene, mutations of the CEBPA gene, and overexpression of the BAALC gene-have been found to predict outcome in patients with AML and normal cytogenetics.
|
15604894 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Baalc, a marker of mesoderm and muscle.
|
15749074 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We conclude that high BAALC expression predicts an adverse prognosis and may define an important risk factor in AML with normal cytogenetics.
|
12750167 |
2003 |
|
Acute Myeloid Leukemia, M1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia.
|
19822134 |
2010 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.300 |
Biomarker
|
disease |
CTD_human |
Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia.
|
19822134 |
2010 |
|
Malignant tumor of colon
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.
|
29698419 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.
|
29698419 |
2018 |
|
Colorectal Neoplasms
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.
|
29698419 |
2018 |
|
Malignant neoplasm of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.
|
29698419 |
2018 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.
|
29698419 |
2018 |
|
Adenocarcinoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.
|
29698419 |
2018 |
|
COLORECTAL CANCER, SUSCEPTIBILITY TO, 1
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.
|
29698419 |
2018 |
|
COLORECTAL CANCER, SUSCEPTIBILITY TO, 10
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.
|
29698419 |
2018 |
|
COLORECTAL CANCER, SUSCEPTIBILITY TO, 3
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.
|
29698419 |
2018 |
|
COLORECTAL CANCER, SUSCEPTIBILITY TO, 12
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.
|
29698419 |
2018 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High BAALC gene expression has been associated with poor prognosis in cytogenetically normal acute myeloid leukaemia (CN-AML) and has been suggested as a suitable marker for assessing minimal residual disease (MRD).
|
27662611 |
2016 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We previously reported that SPARC was among the most upregulated genes in cytogenetically normal acute myeloid leukemia (CN-AML) patients with gene-expression profiles predictive of unfavorable outcome, such as mutations in isocitrate dehydrogenase 2 (IDH2-R172) and overexpression of the oncogenes brain and acute leukemia, cytoplasmic (BAALC) and v-ets erythroblastosis virus E26 oncogene homolog (ERG).
|
24590286 |
2014 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Higher BAALC expression and FLT3-ITD mutation, both individually and in combination, were associated with worse survival outcomes in CN-AML, and this was also applicable in NPM1-mutated CN-AML, known as a favorable-risk group.
|
23647058 |
2014 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To gain further biological insights, we derived a GAS6-associated gene-expression signature (P<0.001) that in GAS6+ patients included overexpressed BAALC and MN1, known to confer adverse prognosis in CN-AML, and overexpressed CXCL12, encoding stromal cell-derived factor, and its receptor genes, chemokine (C-X-C motif) receptor 4 (CXCR4) and CXCR7.
|
24326683 |
2014 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of brain and acute leukemia cytoplasmic (BAALC) gene confers poor prognosis in cytogenetically normal acute myeloid leukemia (AML) patients, while less defined is its role in AML with abnormal karyotype.
|
23760853 |
2013 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of BAALC, ERG, and MN1 is associated with outcome in normal karyotype acute myeloid leukemia (AML).
|
22072540 |
2012 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of MN1, ERG, BAALC, and EVI1 (MEBE) genes in cytogenetically normal acute myeloid leukemia (AML) patients is associated with poor prognosis, but their prognostic effect in patients with myelodysplastic syndromes (MDS) has not been studied systematically.
|
22488406 |
2012 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of the present study show that high expression of miR-3151 is an independent prognosticator for poor outcome in CN-AML and affects different outcome end points than its host gene, BAALC.
|
22529287 |
2012 |
|
Cytogenetically normal acute myeloid leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
20841507 |
2010 |